NeOnc Technologies, Inc.

The company’s lead compound is NEO100 which is a highly purified GMP produced intranasal perillyl alcohol (POH) which is in Phase I/IIa trial in recurrent GBM. The intranasal route is a novel delivery route which can also be used as a solvent for other drugs to the CNS as well. NEO100 has been awarded Fast Track and Orphan Drug Status by the FDA. It is currently finishing Cohort 3/4 for the Phase I trial. Of the eight patients enrolled with long term follow up, 3/8 pat...ients have survived more than seven months with intranasal NEO100 alone (one patient out for 14 months). Intranasal NEO100 is also planned for clinical trials in pediatric brainstem gliomas and skull base tumors. In translational studies, NEO100 may also be delivered intra-arterially, and experiments have demonstrated in rodent models that intra-arterial NEO100 transiently opens up the BBB for 4 hours, and is capable of allowing non-BBB permeable small molecules (i.e., dopamine, doxorubicin), antibodies (Herceptin, anti-PD1), and CAR T cells. This intra-arterial delivery route will be studied via a Phase 1 trial in patients with CNS cancers.

Check out our new article at NeOnctech.com: NEO412 effectively killed melanoma cells In vitro, including TMZ-resistant and BRAF mutant ones, through DNA alkylation and subsequent apoptosis and In vivo, NEO412 inhibited tumor growth when applied topically to the skin of tumor-bearing animals. Titled: NEO412: A temozolomide analog with transdermal activity in melanoma in vitro and in vivo

Check out our new article at NeOnctech.com: The natural compound perillyl alcohol (POH) shows a remarkable ability to circumventing the obstacle posed by the BBB to reach the brain via direct nose-to-brain transport. Titled: Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development

NEO100's clinical trial is starting the third cohort of dosing.

A statement from the American Brain Tumor Association regarding Sen John McCain and Glioblastoma http://hope.abta.org/site/MessageViewer

Amazing details of the human brain.

Evidence is mounting.

A new article from Cancer Letters: A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells https://www.neonctech.com/news

NeOnc Technologies is currently conducting clinical trials for the following products: NEO100 Glioma Study (The Cleveland Clinic) ClinicalTrials.Gov NCT02704858 https://www.neonctech.com/clinical-trials-qualifications

We believe this is the first demonstration of a potentially successful therapeutic treatment of the optic nerve using intranasal delivery of large molecular weight biomolecules, commented Larry Brown, Sc.D., Chief Scientific Officer of Noveome http://www.businesswire.com/news/home/20170131005641/en